Earnings are growing at BioMarin Pharmaceutical (NASDAQ:BMRN) but shareholders still don't like its prospects
Passive investing in an index fund matches the market returns, while individual stocks can do better or worse. BioMarin Pharmaceutical's share price is down 34% in a year, despite revenue growth of 19%. Investor sentiment affects stock prices, and fundamental metrics may reveal market overreactions.